We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Clover Health Investments, Corp. (CLOV) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Clover Health Investments, Corp. (CLOV - Free Report) closed at $8.20 in the latest trading session, marking a +1.86% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.24%.
Prior to today's trading, shares of the company had lost 37.93% over the past month. This has lagged the Medical sector's loss of 2.6% and the S&P 500's gain of 4.09% in that time.
CLOV will be looking to display strength as it nears its next earnings release, which is expected to be August 11, 2021.
Any recent changes to analyst estimates for CLOV should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 24.24% lower. CLOV is currently sporting a Zacks Rank of #4 (Sell).
The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 240, which puts it in the bottom 6% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Clover Health Investments, Corp. (CLOV) Outpaces Stock Market Gains: What You Should Know
Clover Health Investments, Corp. (CLOV - Free Report) closed at $8.20 in the latest trading session, marking a +1.86% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.24%.
Prior to today's trading, shares of the company had lost 37.93% over the past month. This has lagged the Medical sector's loss of 2.6% and the S&P 500's gain of 4.09% in that time.
CLOV will be looking to display strength as it nears its next earnings release, which is expected to be August 11, 2021.
Any recent changes to analyst estimates for CLOV should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 24.24% lower. CLOV is currently sporting a Zacks Rank of #4 (Sell).
The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 240, which puts it in the bottom 6% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.